|
Hall A - PLENARY LECTURES |
|
Thursday, April 11, 2013 |
 |
|
|
|
|
|
|
|
On Sextus Empiricus and medical skepticism
S. Baloyannis, Greece |
Is neurorecovery a valid concept?
D. Muresanu, Romania |
|
|
|
|
|
|
Friday, April 12, 2013 |
|
|
|
|
|
|
|
|
Is AIS evaluation-multimodal CT superior to MRI?
Yes: K. Butcher, Canada |
Is AIS evaluation
multimodal CT
superior to MRI?
No: L. Ranganathan,
India |
Is AIS evaluation
multimodal CT
superior to MRI?
Commentator:
D. Heiss, Germany |
AF-related stroke should be treated only with new anticoagulants
Yes: A. Shuaib, Canada
|
|
|
|
|
|
|
|
|
AF-related stroke should be treated only with new anticoagulants
No: K. Kutluk, Turkey
|
AF-related stroke should be treated only with new anticoagulants
Commentator:
M. Brainin, Austria |
PFO - to close
or not to close?
To close:
N. Uzuner, Turkey |
PFO - to close
or not to close?
Not to close:
L. Csiba, Hungary |
|
|
|
|
|
|
|
|
PFO - to close
or not to close?
Commentator:
N. Bornstein, Israel |
Expensive mistakes in stroke thrombolysis
J. Norris, UK |
Expensive mistakes in stroke thrombolysis
Commentator:
D. Spence, Canada |
|
|
|
Hall A - MULTIPLE SCLEROSIS |
|
Saturday, April 13, 2013 |
|
|
|
|
|
|
|
Are the present outcome measures for assessing efficacy of disease modifying therapies in MS clinically relevant?
Debate host:
C. Hawkes, UK |
Are the present outcome measures for assessing efficacy of disease modifying therapies in MS clinically relevant?
Yes: O. Aktas, Germany
|
Will environmental and behavioral changes alter susceptibility or
the course of MS?
G. Ebers, UK
|
Is disability progression in MS due to an inflammatory or neurodegenerative process?
A. Bar-Or, Canada
|
|
|
|
|
|
|
|
|
|
|
|
Is disability progression in MS due to an inflammatory or neurodegenerative process?
An inflammatory disease: W. Brück, Germany |
Is disability progression in MS due to an inflammatory or neurodegenerative process?
A neurodegenerative disease:
A. Chaudhuri, UK |
MS - Environmental or genetic?
MS is primarily a genetic process: G. Ebers, UK |
MS - Environmental or genetic?
MS is primarily an environmental process:
C. Hawkes, UK |
 |
|
|
|
|
|
|
Primary progressive MS and secondary progressive MS are different manifestations of a single disease
Debate host:
R. Milo, Israel |
Primary progressive MS and secondary progressive MS are different manifestations of a single disease
Yes: O. Kantarci, USA |
Primary progressive MS and secondary progressive MS are different manifestations of a single disease
No: A. Chaudhuri, UK |
Are MS and NMO two polarized diseases? Does this have treatment implications?
Debate host:
M. Keegan, USA |
|
|
|
|
|
|
|
|
Are MS and NMO two polarized diseases? Does this have treatment implications?
Yes: B. Weinshenker, USA |
Are MS and NMO two polarized diseases? Does this have treatment implications?
No: W. Brück, Germany |
Changing perspectives in MS: Pursuing efficacy; managing risk
P. Vermersch, France |
Targeted therapy in MS: Should we aim at B or T lymphocytes?
Therapy should be targeted against B cells:
A. Bar-Or, Canada |
|
|
|
|
|
|
|
|
|
|
|
Radiologically isolated syndrome (RIS) patients are at high risk of developing MS and warrant treatment
with disease
modifying drugs (DMD)
Debate host:
P. Vermersch, France |
Radiologically isolated syndrome (RIS) patients are at high risk of developing MS and warrant treatment with disease modifying
drugs (DMD)
No: A. Siva, Turkey |
New Players in MS
Gilenya:
G. Akman Demir,
Turkey |
New C
New Players in MS
Teriflunomide:
M. Freedman, Canada |
|
|
|
|
|
|
|
|
|
|
New Players in MS
BG12:
O. Bajenaru, Romania |
New Players in MS
Alemtuzumab:
E. Havrdova,
Czech Republic |
New Players in MS
Laquinimod:
H.-P. Hartung, Germany |
New Players in MS
Ocrelizumab:
D. Leppert, Switzerland |
|
|
|
|
|
|
|
|
|
|
|
New Players in MS
Daclizumab: R. Milo, Israel |
|
|
|
|
|
|
|
|
Hall C - PARKINSON'S DISEASE |
|
Friday, April 12, 2013 |
|
|
|
|
|
|
|
|
Is MCI-PD a useful diagnosis?
Yes: M. Emre, Turkey |
Is MCI-PD a useful diagnosis?
No: A.D. Korczyn, Israel |
Are the current outcome parameters in PD clinical trials clinically relevant?
Commentator;
M. Emre, Turkey |
Is molecular imaging really helpful in diagnosing PD?
Yes: A. Antonini, Italy
|
|
|
|
|
|
|
|
|
|
|
|
Is molecular imaging really helpful in diagnosing PD?
No: V. Srinivasan, India
|
Is molecular imaging really helpful in diagnosing PD?
Commentator:
L. Battistin, Italy |
Which is the better dopaminomimetic therapy in PD?
Oral TBN:
L. Vecsei, Hungary |
Which is the better dopaminomimetic therapy in PD?
Transdermal:
A. Antonini, Italy |
|
|
|
|
|
|
|
|
|
|
|
Which is the better dopaminomimetic therapy in PD?
Commentator:
M. Onofrj, Italy |
All PD patients should start treatment with levodopa and go slow
No: C. Akbostanci, Turkey |
All PD patients should start treatment with levodopa and go slow
Commentator:
M. Emre, Turkey |
Do vascular factors influence the
course of PD?
Yes: I. Rektor, Czech Republic |
|
|
|
|
|
|
|
|
|
Do vascular factors influence the
course of PD?
Commentator:
K. Jellinger, Austria |
How large is the advanced space of PD, when does it really start in PD?
View 2: T. van Laar, The Netherlands |
How large is the advanced space of PD, when does it really start in PD?
Commentator:
M. Emre, Turkey |
When should DBS for PD be initiated?
D. Binder, USA |
|
|
|
|
|
|
|
|
|
|
When should DBS for PD be initiated?
B. Elibol, Turkey |
When should DBS for PD be initiated
Commentator: V.Srinivasan, India |
Adjunctive therapy should be initiated as soon as wearing-off is detected
No: B. Elibol, Turkey
|
Adjunctive therapy should be initiated as soon as wearing-off is detected
R. Inzelberg, Israel |
|
|
|
|
|
|
|
|
|
|
|
Debate: NMDA antagonists are useful in PD
Yes: L. Vecsei, Hungary |
Debate: NMDA antagonists are useful in PD
No: M. Onofrj, Italy |
Debate: NMDA antagonists are useful in PD
Commentator:
R. Inzelberg, Israel |
|
|
|
|
|
|
|
|
|
Saturday, April 13, 2013 |
|
|
|
|
|
|
|
|
Does genetic testing have a role in epilepsy management?
Yes: P. Striano, Italy |
Does genetic testing have a role in epilepsy management?
Commentator:
I. Blatt, Israel |
Should patients with cortical strokes be treated prophylactically against seizures?
Yes: N. Dericioglu, Turkey |
Should patients with cortical strokes be treated prophylactically against seizures?
No: W. Theodore, USA |
|
|
|
|
|
|
|
|
Should patients with cortical strokes be treated prophylactically against seizures?
Commentator:
K. Agan, Turkey |
EEG is usually necessary when diagnosing epilepsy
No: M. Holtkamp, Germany |
EEG is usually necessary when diagnosing epilepsy
Commentator:
V. Kimiskidis, Greece |
Who should have drugs stopped and who should be continued?
Speaker:
C. Ozkara, Turkey |
|
|
|
|
|
|
|
|
Who should have drugs stopped and who should be continued?
Commentator:
E. Ben-Menachem, Sweden |
Proposition: DBS should only be used after VNS has failed
Yes: M. Sperling, USA |
Proposition: DBS should only be used after VNS has failed
No: P. Boon, Belgium |
Proposition: DBS should only be used after VNS has failed
Commentator:
M. Holtkamp, Germany |
|
|
|
|
|
|
|
Are some antiepileptic drugs preferred during pregnancy?
Yes: V. Kimiskidis, Greece |
Are some antiepileptic drugs preferred during pregnancy?
No: E. Beghi, Italy |
Are some antiepileptic drugs preferred during pregnancy?
Commentator:
E. Ben-Menachem, Sweden |
Should enzyme-inducing antiepileptic drugs be avoided?
Yes: M. Sperling, USA |
|
|
|
|
|
|
|
|
Should enzyme-inducing antiepileptic drugs be avoided?
No: W. Theodore, USA |
Should enzyme-inducing antiepileptic drugs be avoided?
Commentator:
E. Beghi, Italy |
Is aggressive therapy justified for all types of status epilepticus?
Yes: K. Agan, Turkey
|
Is aggressive therapy justified for all types of status epilepticus?
No: P. Boon, Belgium |
